Allergen specific immunotherapy

PreclinicalBiologic

UUniversity of Zurich

Allergen specific immunotherapy is one of 32 biologic programs targeting Allergy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPreclinical

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Allergy

#DrugCompanyPhaseTrials

Flovent

GSK

Phase 3

1 2

Clarinex

OOrganon and Co

Phase 3

1 3

Xolair

Roche

Phase 2

7 4

REGN5713

Regeneron

Phase 3

1 5

REGN5715

Regeneron

Phase 3

1 6

Rhapsido

Novartis

Phase 2

1 7

Ligelizumab

Novartis

Phase 3

1 8

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

3 9

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

1 10

Elspar

DDutch Childhood Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Not yet recruiting

Pollen Allergy

NCT06876506

Clinical

Trials by Indication[1]

Immunotherapy1 trial

A Randomized Study to Evaluate a Novel Method of Specific Allergen Immunotherapy

Completed·UUniversity of Zurich·Phase 2·NCT00470457·156 enrolled

Allergy1 trial

The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy

Unknown status·UUniversitas Airlangga·N/A·NCT05450289·40 enrolled

Pollen Allergy1 trial

Identification and Quantitation of Human B Regulatory Cells Via Flow Cytometry and Their Potential Role as a Treatment Efficacy Biomarker in Allergen-specific Immunotherapy

Not yet recruiting·HHull University Teaching Hospitals NHS Trust··NCT06876506·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Allergen specific immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allergen specific immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allergen specific immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Zurich

Allergen specific immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Immunotherapy1 trial

Allergy1 trial

Pollen Allergy1 trial

References

Drug Info

Quick Facts

Related News